553 results on '"Cihlar, Tomas"'
Search Results
2. Antiviral target compound profile for pandemic preparedness
3. Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
4. Effect of remdesivir post-exposure prophylaxis and treatment on pathogenesis of measles in rhesus macaques
5. No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta
6. VEKLURY®(REMDESIVIR), A NUCLEOTIDE PRODRUG APPROVED FOR THE TREATMENT OF COVID-19
7. Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control
8. Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection
9. Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
10. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
11. A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
12. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
13. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir
14. Remdesivir: Investigational Antiviral Drug with Activity Against Ebola and Other Emerging and Neglected Viruses
15. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
16. The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses
17. Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability
18. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus
19. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
20. Clinical targeting of HIV capsid protein with a long-acting small molecule
21. Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection
22. Author Correction: A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
23. Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus
24. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
25. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
26. A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome
27. Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment
28. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model
29. Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment
30. Characterization of the Cynomolgus Macaque Model of Marburg Virus Disease and Assessment of Timing for Therapeutic Treatment Testing
31. 539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir
32. Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent
33. Discovery of GS-7682, a Novel 4′-Cyano-Modified C-Nucleoside Prodrug with Broad Activity against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green Monkeys
34. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
35. Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting
36. Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys
37. Late remdesivir treatment initiation partially protects African green monkeys from lethal Nipah virus infection
38. Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential
39. Current status and prospects of HIV treatment
40. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
41. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat
42. Blood biomarkers of expressed and inducible HIV-1
43. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
44. Sugar-modified derivatives of cytostatic 7-(het)aryl-7-deazaadenosines: 2′-C-methylribonucleosides, 2′-deoxy-2′-fluoroarabinonucleosides, arabinonucleosides and 2′-deoxyribonucleosides
45. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
46. Bulevirtide is broadly active against all HDV genotypes expressing envelopes from HBV genotypes A-H and a large panel of clinical isolates
47. The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2
48. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
49. Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2
50. Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.